BTIG initiates Lyra coverage with 'buy'
06/10/2023 15:37
** Brokerage BTIG initiates coverage of drug developer Lyra
Therapeutics LYRA.O with "buy" rating, sets PT at $15
** The price target represents an upside more than double
the stock's last close at $3.94
** BTIG sees significant potential for co's products
LYR-210 and LYR-220 in chronic rhinosinusitis (CRS), a condition
that is characterized by inflammation of the paranasal sinuses
** Six brokerages rate the stock "buy" or higher; their
median PT is $15 - LSEG data
** Including session's moves, stock up ~22% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))